1034494-08-0

Upstream product

• 67853-01-4 benzyl 4-(hydroxymethyl)benzoate 
• 124-63-0 methanesulfonyl chloride 
• 100-39-0 benzyl bromide 
• 3006-96-0 3-hydroxymethyl-benzoic acid 

Downstream Products

• 1034494-12-6 4-[1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethyl] benzoic acid benzyl ester 
• 1034494-18-2 4-[1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethyl] benzoic acid 
• 1196982-54-3 N-(4-aminothiophen-3-yl)-4-[1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethyl]benzamide 
• 1422008-84-1 benzyl 4-(2-methoxycarbonyl-4-methyl-3-oxopentyl)benzoate 
• 1422008-57-8 C₂₀H₂₇N₃O₇ 
• 1422008-44-3 4-[3-(tetra-O-acetyl-β-d-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]benzoic acid 
• 1422008-38-5 benzyl 4-(1,2-dihydro-3-oxo-5-isopropyl-3H-pyrazol-4-ylmethyl)benzoate 
• 1422008-45-4 benzyl 4-[3-(tetra-O-acetyl-β-d-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]benzoate 
• 1034494-09-1 4-(2-dimethylaminoethylaminomethyl)benzoic acid benzyl ester 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-d-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1)

Sodium glucose co-transporter 1 (SGLT1) plays a dominant role in the absorption of glucose in the gut and is considered a promising target in the development of therapeutic options for postprandial hyperglycemia. Previously, we reported potent and selective SGLT1 inhibitors 1 and 2 showing efficacy in oral carbohydrate tolerance tests in diabetic rat models. In a pharmacokinetic (PK) study of 2, excessive systemic exposure to metabolites of 2 was observed, presumably due to the high permeability of its aglycone (2a). To further improve SGLT1 inhibitory activity and reduce aglycone permeability, a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-d-glycopyranoside derivatives bearing novel hydrophilic substitution groups on the phenyl ring were synthesized and their inhibitory activity toward SGLTs was evaluated. Optimized compound 14c showed an improved profile satisfying both higher activity and lower permeability of its aglycone (22f) compared with initial leads 1 and 2. Moreover, the superior efficacy of 14c in various carbohydrate tolerance tests in diabetic rat models was confirmed compared with acarbose, an α-glucosidase inhibitor (α-GI) widely used in the clinic.

NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE

The present invention relates to synthetic studies of a novel thiophenediamine derivative having a urea structure and to finding pharmaceutical actions thereof. The present invention provides a compound represented by the following general formula (1) or

NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE

The present invention relates to a study on the sy nthesis of a novel N-(2-aminophenyl)benzamide derivativ e having an urea structure and represented by the genera l formula (1); and the utilization of a pharmacological effect of the derivative. A compoun